Comparative Pharmacology
Head-to-head clinical analysis: ORETON METHYL versus VIRILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORETON METHYL versus VIRILON.
ORETON METHYL vs VIRILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyltestosterone is a synthetic androgen that binds to androgen receptors, activating transcription of androgen-responsive genes, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development.
Testosterone replacement therapy; binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics.
10-50 mg orally or buccally 1-3 times daily; or 25-100 mg IM every 2-4 weeks.
200 mg intramuscularly every 2 weeks for androgen replacement therapy in adult males.
None Documented
None Documented
Terminal half-life approximately 2.7–3.8 hours; brief due to rapid hepatic metabolism.
Terminal elimination half-life is approximately 3–4 hours for methyltestosterone; however, the pharmacologic effect persists longer due to active metabolites, supporting once-daily dosing.
Primarily renal as conjugated metabolites; ~90% urinary, ~6% fecal within 4 days.
Approximately 90% of administered methyltestosterone is excreted as glucuronide and sulfate conjugates in urine; less than 5% appears in feces as unchanged drug and metabolites.
Category C
Category C
Androgen
Androgen